Flavia Castro Velasco Fernandes

Flavia Castro Velasco Fernandes

Auto-generated profile, based on publicly available information

Flavia Castro Velasco Fernandes

Faculdade de Medicina, Universidade Federal de Goiás Goiânia Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
SMSimone Lobo Krupok Matias
Simone Lobo Krupok Matias
CPCarlos Alberto de Castro Pereira
Carlos Alberto de Castro Pereira
MSMaria Raquel Soares
Maria Raquel Soares
FFFlavia Castro Velasco Fernandes
Flavia Castro Velasco Fernandes
MMMaria Auxiliadora Carmo Moreira
Maria Auxiliadora Carmo Moreira
EMEliane Viana Mancuzo
Eliane Viana Mancuzo
Objective: To assess the relative frequency of incident cases of interstitial lung diseases (ILDs) in Brazil. Methods: This was a retrospective survey of new cases of ILD in six referral centers between January of 2013 and January of 2020. The diagnosis of ILD followed the criteria suggested by international bodies or was made through multidisciplinary discussion (MDD). The condition was characterized as unclassifiable ILD when there was no specific final diagnosis following MDD or when there was disagreement between clinical, radiological, or histological data. Results: The sample comprised 1,406 patients (mean age = 61 +/- 14 years), and 764 (54%) were female. Of the 747 cases exposed to hypersensitivity pneumonitis (HP)-related antigens, 327 (44%) had a final diagnosis of HP. A family history of ILD was reported in 8% of cases. HRCT findings were indicative of fibrosis in 74% of cases, including honeycombing, in 21%. Relevant autoantibodies were detected in 33% of cases. Transbronchial biopsy was performed in 23% of patients, and surgical lung biopsy, in 17%. The final diagnoses were: connective tissue disease-associated ILD (in 27%), HP (in 23%), idiopathic pulmonary fibrosis (in 14%), unclassifiable ILD (in 10%), and sarcoidosis (in 6%). Diagnoses varied significantly among centers (chi(2) = 312.4; p < 0.001). Conclusions: Our findings show that connective tissue disease-associated ILD is the most common ILD in Brazil, followed by HP. These results highlight the need for close collaboration between pulmonologists and rheumatologists, the importance of detailed questioning of patients in regard with potential exposure to antigens, and the need for public health campaigns to stress the importance of avoiding such exposure.

1 April 2025 in Science Progress
Verified
Journal Article
Open access
DFDaniel Cesar M Fernandes
Daniel Cesar M Fernandes
FVFlavia Velasco
Flavia Velasco
LFLucas Velasco Magalhaes Fernandes
Lucas Velasco Magalhaes Fernandes
MBMatheus Bertanha
Matheus Bertanha
MSMarcone Lima Sobreira
Marcone Lima Sobreira
Objective: The potential benefit of measures to prevent contrast-induced acute kidney injury (CIAKI) remains uncertain. This uncertainty is partly due to the reliance on serum creatinine, a biomarker influenced by non-renal factors such as muscle mass, hydration status, and age. Therefore, this study aims to evaluate CIAKI prevention based on cystatin C levels—a more stable and earlier biomarker of renal dysfunction, which may improve diagnostic precision and the assessment of therapeutic efficacy. Methods: We performed a systematic review and meta-analysis of all randomized clinical trials (RCTs) on preventive measures of contrast-induced acute kidney injury, based on cystatin C levels, in patients who underwent percutaneous procedures. We searched PubMed, Scopus, and Cochrane Central for studies comparing the use of high-dose statins in prevention. The outcome of interest was an acute kidney injury based on increased serum cystatin C after the procedure. Statistical analysis was performed using RevMan 5.4. This systematic review with meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under protocol (CRD42023441815). Results: We included four studies with a total of 1167 patients, of whom 594 (50.8%) received high-dose statins (atorvastatin or rosuvastatin). On the baseline characteristics of the study population, 65% were male; 79.2% had hypertension; 44.3% had diabetes; 35.7% had dyslipidemia, and 35.4% were currently smokers. Overall, high doses of statins were associated with a lower incidence the CIAKI (OR 0.31; 95% CI [0.19,0.53]; P < .0001). Conclusion: Our findings suggest that high doses of statins may play an important role as a measure to prevent CIAKI. If this result is confirmed, we will be able to set up CIAKI prevention protocols, thus expanding the number of patients who will undergo contrast-enhanced exams.

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
RMRoman Rodriguez Milan
Roman Rodriguez Milan
NNNyree Nava Nogueda
Nyree Nava Nogueda
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
AAAshfaq Ahmad
Ashfaq Ahmad
EEErik E. Chiong Espinoza
Erik E. Chiong Espinoza
FFFlavia Castro Velasco Fernandes
Flavia Castro Velasco Fernandes
Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which eosinophilic inflammation represents a treatable trait associated with increased exacerbation risk. Randomized trials (RCTs) of mepolizumab in eosinophilic COPD have shown variable results, and the magnitude of clinical benefit remains uncertain.MethodsWe performed a systematic review and meta-analysis of RCTs evaluating mepolizumab in eosinophilic COPD. Frequentist random-effects models were used to estimate pooled effects, and complementary Bayesian analyses were conducted to quantify the probability of treatment benefit.ResultsFour RCTs comprising 1,953 patients of whom 978 (50.1%) underwent mepolizumab were analyzed. Mepolizumab significantly reduced the annual rate of moderate or severe exacerbations (IRR 0.80; 95% CI: 0.75 to 0.86) and prolonged the time to first exacerbation (HR 0.78: 95% CI: 0.69 to 0.88). Bayesian analyses showed a posterior probability of high benefit for exacerbation-related outcomes. Similarly, a reduction in exacerbations requiring emergency care was observed (IRR 0.77; 95% CI: 0.60 to 1.00) with no increased risk for adverse events, treatment discontinuation, or mortality. Conclusion In eosinophilic COPD, mepolizumab reduces exacerbation frequency and delays time to first exacerbation without compromising safety. These findings support targeting IL-5-mediated eosinophilic inflammation in selected COPD populations.

3 September 2026 in Respirology Case Reports
Verified
Journal Article
Open access
FFFlavia Castro Velasco Fernandes
Flavia Castro Velasco Fernandes
PTPedro Paulo Teixeira e Silva Torres
Pedro Paulo Teixeira e Silva Torres
ESElisângela Silveira-Lacerda
Elisângela Silveira-Lacerda
MRMatheus Rabahi
Matheus Rabahi
LFLucas Velasco Magalhaes Fernandes
Lucas Velasco Magalhaes Fernandes
MRMarcelo Fouad Rabahi
Marcelo Fouad Rabahi
COPA syndrome is a rare autosomal dominant autoimmune disorder caused by COPA gene mutations, leading to immune dysregulation and multisystem involvement. We report a 45‐year‐old man with recurrent respiratory failure, haemoptysis, renal dysfunction and arthritis. Symptoms began at Age 27 with diffuse alveolar damage requiring mechanical ventilation. Imaging showed progressive interstitial lung disease and biopsy revealed follicular bronchiolitis. Immunosuppression provided temporary stabilisation. In 2024, next‐generation sequencing confirmed a likely pathogenic COPA variant. The patient later discontinued therapy and remained untreated for 1 year, returning with worsening renal dysfunction and significant proteinuria, while pulmonary findings remained stable. Cyclophosphamide was initiated for suspected renal relapse. During treatment, he developed acute diverticulitis complicated by sepsis, progressing to septic shock and multiorgan failure despite surgery and antibiotics, resulting in death. Early recognition and multidisciplinary management are essential to improve outcomes of the disease.

17 December 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
PTPedro Paulo Teixeira e Silva Torres
Pedro Paulo Teixeira e Silva Torres
PAPaula Terra Martins Almeida Amaral
Paula Terra Martins Almeida Amaral
AHAlan Diniz Hummel
Alan Diniz Hummel
EFEduardo Kaiser Ururahy Nunes Fonseca
Eduardo Kaiser Ururahy Nunes Fonseca
RCRodrigo Caruso Chate
Rodrigo Caruso Chate
EMEdson Santos Marchiori
Edson Santos Marchiori
Patients diagnosed with fibrosing interstitial lung disease are at risk of several complications, some of which may be life-threatening. Computed tomography imaging plays an important role in diagnosing these overlapping conditions. This article summarizes the computed tomography imaging features of the most common conditions associated with fibrosing interstitial lung diseases, categorized by involvement of the lung parenchyma or extra-pulmonary compartments. Some steps may help to recognize such complications, such as having knowledge of the underlying fibrotic lung disease, being